BiotechTube

Peginterferon alfa-2a

Phase 2Terminated
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Myelofibrosis

Conditions

Myelofibrosis

Trial Timeline

Jan 1, 2013 → Jun 1, 2017

NCT ID
NCT01758588

About Peginterferon alfa-2a

Peginterferon alfa-2a is a phase 2 stage product being developed by Merck for Myelofibrosis. The current trial status is terminated. This product is registered under clinical trial identifier NCT01758588. Target conditions include Myelofibrosis.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT01758588Phase 2Terminated

Competing Products

20 competing products in Myelofibrosis

See all competitors
ProductCompanyStageHype Score
Ruxolitinib + AbemaciclibEli LillyPhase 1
33
Nusivertib + Ruxolitinib + MomelotinibSumitomo PharmaPhase 1/2
41
Ruxolitinib + NavitoclaxAbbViePhase 2
52
ABBV-744 + Navitoclax + RuxolitinibAbbViePhase 1
33
Placebo for Navitoclax + Ruxolitinib + NavitoclaxAbbViePhase 3
77
Mivebresib + Navitoclax + RuxolitinibAbbViePhase 1
33
Navitoclax + VenetoclaxAbbViePre-clinical
23
Navitoclax + Ruxolitinib + Best Available Therapy (BAT)AbbViePhase 3
77
NS-018 + Best Available TherapyNippon ShinyakuPhase 2
52
AZD1480AstraZenecaPhase 1
33
BomedemstatMerckPhase 2
52
BomedemstatMerckPhase 1/2
41
MBG453 + NIS793 + Spartalizumab + DecitabineNovartisPhase 1
33
PIM447 + Ruxolitinib + LEE011NovartisPhase 1
33
LDE225 + INC424NovartisPhase 1/2
41
Imatinib mesylateNovartisPhase 2
52
Ruxolitinib + Siremadlin + Crizanlizumab + Sabatolimab + Rineterkib + NIS793NovartisPhase 1/2
41
Ruxolitinib + Ruxolitinib PlaceboNovartisPhase 3
77
RuxolitinibNovartisPre-clinical
23
ruxolitinibNovartisPhase 2
52

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85